Cargando…

Evaluating the Safety, Efficacy and Patient Acceptability of Intravitreal Fluocinolone Acetonide (0.2mcg/Day) Implant in the Treatment of Non-Infectious Uveitis Affecting the Posterior Segment

Long-acting, slow-release injectable fluocinolone intravitreal implants have been approved for the treatment of non-infectious uveitis affecting the posterior segment. We summarise the development of intravitreal fluocinolone implants and discuss the technology including pharmacokinetics. We conduct...

Descripción completa

Detalles Bibliográficos
Autores principales:	Steeples, Laura R, Pockar, Sasa, Jones, Nicholas P, Leal, Inês
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8039205/ https://www.ncbi.nlm.nih.gov/pubmed/33854297 http://dx.doi.org/10.2147/OPTH.S216912

Ejemplares similares

Long-Acting Fluocinolone Acetonide Intravitreal Implant for Recurrent Bilateral Non-Infectious Posterior Uveitis
por: Babel, Adrian T, et al.
Publicado: (2022)

Intravitreal 0.19 mg Fluocinolone Acetonide Implant in Non-Infectious Uveitis
por: Hikal, Muaas, et al.
Publicado: (2021)

Preventing relapse in non-infectious uveitis affecting the posterior segment of the eye – evaluating the 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN(®))
por: Bodaghi, Bahram, et al.
Publicado: (2020)

The 0.2-μg/day Fluocinolone Acetonide Intravitreal Implant in Chronic Noninfectious Posterior Uveitis: A 3-year Randomized Trial in India
por: Biswas, Jyotirmay, et al.
Publicado: (2023)

Post-cataract outcomes in patients with noninfectious posterior uveitis treated with the fluocinolone acetonide intravitreal implant
por: Sheppard, John D, et al.
Publicado: (2012)

Intravitreal methotrexate and fluocinolone acetonide implantation for Vogt-Koyanagi-Harada uveitis
por: Park, Jong G., et al.
Publicado: (2020)

Non-infectious uveitis affecting the posterior segment treated with fluocinolone acetonide intravitreal implant: 3-year fellow eye analysis
por: Pavesio, Carlos, et al.
Publicado: (2021)

Real-world experience with 0.2 μg/day fluocinolone acetonide intravitreal implant (ILUVIEN) in the United Kingdom
por: Bailey, C, et al.
Publicado: (2017)

Intravitreal fluocinolone acetonide 0.19 mg (ILUVIEN®) in patients with non-infectious uveitis: real-world effectiveness and safety outcomes at 12 months
por: Moll-Udina, Aina, et al.
Publicado: (2023)

Efficacy of 0.19 mg Fluocinolone Acetonide Implant in Non-infectious Posterior Uveitis Evaluated as Area Under the Curve
por: Battista, Marco, et al.
Publicado: (2021)

Fluocinolone acetonide intravitreal implant for the treatment of diabetic macular edema
por: Messenger, Wyatt B, et al.
Publicado: (2013)

Intravitreal Fluocinolone Acetonide May Decelerate Diabetic Retinal Neurodegeneration
por: Lynch, Stephanie K., et al.
Publicado: (2019)

Clinical impact of the 0.2 µg/day fluocinolone acetonide intravitreal implant: outcomes from the ILUVIEN(®) clinical evidence study in Portugal
por: Carneiro, Angela, et al.
Publicado: (2020)

Fluocinolone Acetonide Intravitreal Implant for Treating Recurrent Non-infectious Uveitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
por: Pouwels, Xavier G. L. V., et al.
Publicado: (2019)

Anterior migration of intravitreal fluocinolone acetonide (Iluvien®) implant in a pseudophakic eye with intact posterior capsule
por: Alzaabi, Manal, et al.
Publicado: (2020)

Use of the Fluocinolone Acetonide Intravitreal Implant for the Treatment of Noninfectious Posterior Uveitis: 3-Year Results of a Randomized Clinical Trial in a Predominantly Asian Population
por: Sangwan, Virender S., et al.
Publicado: (2014)

Injectable 0.19-mg fluocinolone acetonide intravitreal implant for the treatment of non-infectious uveitic macular edema
por: Weber, Lea F., et al.
Publicado: (2019)

Comment on: “Use of the Fluocinolone Acetonide Intravitreal Implant for the Treatment of Noninfectious Posterior Uveitis: 3-Year Results of a Randomized Clinical Trial in a Predominantly Asian Population”
por: Hall, John
Publicado: (2015)

Two-year interim safety results of the 0.2 µg/day fluocinolone acetonide intravitreal implant for the treatment of diabetic macular oedema: the observational PALADIN study
por: Mansour, Sam E, et al.
Publicado: (2021)

Intravitreal fluocinolone acetonide implant (ILUVIEN®) for diabetic macular oedema: a literature review
por: Massa, Horace, et al.
Publicado: (2018)

Sustained Control of Serpiginous Choroiditis with the Fluocinolone Acetonide 0.18 mg Intravitreal Implant
por: Siddiqui, Yousuf, et al.
Publicado: (2022)

Fluocinolone acetonide 0.19-mg implant for the treatment of noninfectious uveitis with involvement of the posterior segment: a real-world study
por: Buhl, Lara, et al.
Publicado: (2022)

Management of Patients with Diabetic Macular Edema Switched from Dexamethasone Intravitreal Implant to Fluocinolone Acetonide Intravitreal Implant
por: Baillif, Stéphanie, et al.
Publicado: (2022)

Scleral fixation of fluocinolone acetonide implant()
por: Tabandeh, Homayoun, et al.
Publicado: (2020)

Long-term follow-up of patients treated with multiple fluocinolone acetonide implants for noninfectious uveitis
por: Allen, Rebekah C., et al.
Publicado: (2012)

Keratoprosthesis, silicone oil placement, and fluocinolone acetonide implant for treatment of uveitis-associated hypotony and keratopathy
por: Mosenia, Arman, et al.
Publicado: (2022)

Fluocinolone acetonide intravitreal sustained release device – a new addition to the armamentarium of uveitic management
por: Brumm, Matthew V, et al.
Publicado: (2007)

Intravitreal Fluocinolone Acetonide for Diabetic Macular Edema: Long-Term Effect and Structure/Function Correlation
por: Minnella, Angelo Maria, et al.
Publicado: (2022)

Intravitreal Fluocinolone Acetonide Implant (ILUVIEN(®)) for the Treatment of Retinal Conditions. A Review of Clinical Studies
por: Mushtaq, Yusuf, et al.
Publicado: (2023)

Efficacy of 0.2 μg/day fluocinolone acetonide implant (ILUVIEN) in eyes with diabetic macular edema and prior vitrectomy
por: Meireles, A, et al.
Publicado: (2017)

Long-Term Follow-Up of Patient with Diabetic Macular Edema Receiving Fluocinolone Acetonide Intravitreal Implant
por: Bertelmann, Thomas, et al.
Publicado: (2015)

Off-Label Use of 0.19 mg Fluocinolone Acetonide Intravitreal Implant: A Systematic Review
por: Ribeiro, Flávio, et al.
Publicado: (2021)

Intraocular Pressure Changes After Intravitreal Fluocinolone Acetonide Implant: Results from Four European Countries
por: Lebrize, Sarah, et al.
Publicado: (2022)

Bilateral 0.19 mg Fluocinolone Acetonide Intravitreal Implant in the Successful Treatment of Juvenile Idiopathic Arthritis-Associated Uveitis and Secondary Macular Oedema: A Case Report and Review of Intravitreal Therapies
por: Ansari, Abdus Samad, et al.
Publicado: (2021)

The USER Study: A Chart Review of Patients Receiving a 0.2 µg/day Fluocinolone Acetonide Implant for Diabetic Macular Edema
por: Eaton, Alexander, et al.
Publicado: (2018)

Real-World Outcomes in Diabetic Macular Edema for the 0.2 µg/Day Fluocinolone Acetonide Implant: Case Series from the Midlands, UK
por: Mushtaq, Bushra, et al.
Publicado: (2021)

Long-term outcomes of phakic patients with diabetic macular oedema treated with intravitreal fluocinolone acetonide (FAc) implants
por: Yang, Y, et al.
Publicado: (2015)

Intravitreal Fluocinolone Acetonide (ILUVIEN) Implant for the Treatment of Refractory Cystoid Macular Oedema After Retinal Detachment Repair
por: Alfaqawi, Fadi, et al.
Publicado: (2018)

Changes in intraocular pressure after intravitreal fluocinolone acetonide (ILUVIEN): real-world experience in three European countries
por: Chakravarthy, Usha, et al.
Publicado: (2019)

Iluvien™ (Fluocinolone Acetonide 0.19 mg Intravitreal Implant) in the Treatment of Diabetic Macular Edema: A Review
por: Fusi-Rubiano, William, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mups50q3i43rjcencjfv29s6ig